4th Annual Gene Therapy for Rare Disorders Europe | 26-28 October, 2020 | Online

Memo

The 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming manufacturing, clinical, and commercialisation challenges drug developers face when delivering gene therapies to market. With new European gene therapy approvals rapidly approaching and investment at an all-time high, the digital meeting will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy, safety and commercial viability. Across three days, we will virtually unite 250+ leading experts from innovative biotechs, large pharmaceutical companies, academia, and key service providers. Understand the nuances of the European regulatory landscape, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come. Wherever you're based, if you're looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward. URLs:Tickets: https://go.evvnt.com/673301-2?pid=5569Brochure: https://go.evvnt.com/673301-3?pid=5569 Prices:Drug Developer Early Rate - Conference Only: GBP 1469.0,Drug Developer Early Rate - Full Access: GBP 1827.0,Drug Developer Final Rate - Conference Only: GBP 1749.0,Drug Developer Final Rate - Full Access: GBP 2247.0 Speakers: Tangir Ahamed, Principal Scientist, uniQure, Gilles Atlan, Vice President, NF2 BioSolutions, Eduard Ayuso, Head of Innovative Vectorology and Scientific Director of the Translational Vector Core, University of Nantes, Michael Binks, Vice President, Rare Disease Clinical Research, Pfizer, Alexandra Brinkman, Lead Research Analyst, Beacon Targeted Therapies, Christina Broomes, Director, Contract Manufacturing, Ultragenyx, Andrea Challand, Director Regulatory Affairs, Roche, Gabriel Cohn, Chief Medical Officer, Homology Medicines, Pierre-Albert Colcomb, Business Development Director, Genethon, Nick Crabb Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE), Claire Davies, Associate Vice President, Sanofi, Jean-Yves Deslandes, Chief Medical Officer, Horama, Anne Douar, Chief Development Officer, Vivet Therapeutics, Ramin Farhood, Vice President, Head of Global Medical Affairs, AveXis, Michela Gabaldo, Head of Alliance Management and Regulatory Affairs, Fondazione Telethon, Magali Gibou, Vice President, Regulatory Affairs, Sangamo Therapeutics, Annie Hubert, Senior Director, European Public Policy, Alliance for Regenerative Medicine, Christeen Moburg, Head of Patient Advocacy, Sangamo Therapeutics Date and Time: On Monday October 26, 2020 at 8:00 am (ends Wednesday October 28, 2020 at 6:00 pm)